Zoom's Selloff Priced the Old Story. The Business Just Inflected.

This week's analyst roundup covered four names — Nvidia, Zoom, SoFi and Dollar Tree — and only one of them set up the pattern this approach hunts: the stock fell while the business improved. Zoom reported second-quarter revenue of $1.28 billion, up 4.9% and a shade above the $1.27 billion consensus, beat profit expectations, and raised its full-year targets — then watched its shares drop to a three-month low near $94 before the week was out.

The market read the three-month number. The business printed the twelve-month one.

To see why that gap is worth your attention, start with what Zoom has become in the market's imagination: the poster child for a pandemic stock with nowhere to go. One product, video meetings; a collapse from nosebleed 2020 valuations; growth that fell to single digits once the world went back to the office. For five years the question was not whether Teams had a better product. It was that Zoom's growth had run out, and the stock was priced to keep running out.

That old story is still in the price. At roughly $99 a share, Zoom carries a market value around $29 billion against the $1.8 billion of free cash flow management guided to for the current fiscal year — about 16 times. Subtract the $7.2 billion of cash and marketable securities on the balance sheet and the operating business trades near 12 times guided free cash flow. That is a no-growth price. A utility's price. Not the price of a company that will keep growing.

What cracked the premise was the quarter itself. Revenue of $1.28 billion beat both the consensus estimate and the top of Zoom's own guidance, but the number inside matters more: enterprise revenue rose 7.8% to $787.5 million — its strongest growth in three years — while the consumer "online" line crawled up 0.6%. Enterprise is now nearly two-thirds of revenue, and the attached customer math is improving: the trailing twelve-month net dollar expansion rate ticked up to 99% from 98%, and the count of customers paying more than $100,000 a year rose 8.2%.

That is what made the quarter a beat and also made the stock a loser. Zoom's guidance for the next quarter came in a hair under expectations — $1.275 to $1.28 billion of revenue against a $1.282 billion estimate, and non-GAAP EPS of $1.46 to $1.48 against $1.50. The market treated two pennies as a verdict. Meanwhile the full-year numbers went the other direction: management raised revenue guidance to $5.085 to $5.095 billion and lifted EPS guidance to $6.08 to $6.12. A soft one-quarter guide landed in a stock that had rallied nearly 30% in the four months before the report — a crowded trade, and the guide hit it. That explains the tape. Timing versus trajectory explains the business.

Here is the part that makes the case concrete, because it is the financial bridge, not the story: Zoom converts roughly 38% of its trailing revenue into free cash flow, printed $472 million of it in the second quarter alone, and guided to $1.78 to $1.82 billion for the year. Against a $29 billion market cap that is the 16 times. And the company is actively returning the cash: $352 million of buybacks in the quarter, about $1.3 billion still authorized. That means you are being paid roughly 6% per year in cash yield by a company carrying about a quarter of its market cap in net cash. This is not about excitement. It is about a business that may soon be a lot harder to dismiss once the free cash flow keeps showing up.

But the wrinkle, and the reason the stock fell, is real, so name it plainly. The guided $1.78 to $1.82 billion of free cash flow for the year is below the trailing run rate of roughly $1.9 billion. Zoom is spending to build its AI platform now, and it is telling you the cash cost lands this year. That is an investment tax. It only pays off if the spending buys accelerating enterprise growth — and the market's bear case is precisely that it will not.

That bear case deserves a fair hearing. Pay 16 times free cash flow for a company whose top line grows 5%, whose near-term profit and cash flow are being squeezed by an expensive AI buildout, and whose core product is a commodity under pressure from better-funded rivals? If that is the trajectory, a utility multiple is generous, and the angry tape is right.

So pin the thesis to the two numbers that decide it. The condition that would break the case is concrete: enterprise revenue growth rolling back toward mid-single digits, net dollar expansion slipping below 99%, or the free cash flow guidance being cut below roughly $1.7 billion. If any of those arrive, the has-been label is earned, and the right move is to cut without ego. Until then this is an expectations reset with a bridge attached: a no-growth multiple on a business whose enterprise engine is accelerating while free cash flow stays near its record.

For what the roundup itself is worth: AInvest's aggregate signal already labels Zoom a buy, and the analysts who moved after the report mostly kept buy ratings with targets of $116 to $130 against a roughly $99 stock — the average target sits near $116. The debate is no longer whether. It is whether the numbers keep arriving.

The way to read this week's four names is to ask which one had its expectations reset while the business kept improving underneath. Not Nvidia — near record levels, nothing needed resetting. Not SoFi — the fresh buy recommendation is for a hyper-growth lender whose cash flow turns negative as loans scale, a story that needs a different kind of proof than free cash flow. Not Dollar Tree — a real free-cash-flow name, but its blowout quarter carried a $383 million tariff refund inside the number, a one-time asterisk on good execution. That leaves Zoom: the one name in the roundup where the market is still pricing the old risk profile while the operating setup is already cleaner.

I can be wrong again — the tape has humbled Zoom holders for five years. But that is exactly the point. The stock fell this week for the wrong reason, and the business kept improving for the right ones. That divergence, not the rating, is the reason to care.